2026 Provider Cost Showdown

OrderlyMeds Tirzepatide Pricing vs. Losing Weight RX

By Claire Bennett, MA • Medically Reviewed by Dr. James Nakamura, MD • Updated November 2026 • 8 min read
$199–$399
OrderlyMeds monthly cost for Semaglutide & Tirzepatide
$3,600/yr
Annual overpayment on OrderlyMeds Tirzepatide ($4,788 vs $1,188)
$49 / $99
Losing Weight RX flat rate (Semaglutide $49/mo · Tirzepatide $99/mo)

Reviewing OrderlyMeds tirzepatide pricing for 2026 shows how flat-rate $99/mo 503A tirzepatide at Losing Weight RX lowers monthly cash-pay expenses without membership fees. If you are comparing OrderlyMeds vs. Losing Weight RX in 2026, you likely noticed that OrderlyMeds markets itself as a 'no-membership-fee' flat-rate provider. While it is true that OrderlyMeds does not charge a separate monthly portal fee like Ro ($145/mo) or Mochi ($79/mo), they bake a massive retail markup directly into the vial price: $199/month for compounded Semaglutide and $399/month for compounded Tirzepatide.

By contrast, Losing Weight RX provides the exact same 503A sterile compounded active peptides, asynchronous U.S. physician review, syringes, and express cold-chain shipping for $49/month flat (Semaglutide) and $99/month flat (Tirzepatide) across every dosage tier from 0.25mg to 2.4mg and 2.5mg to 15mg.

Black Friday Early Access · 83% OFF

Skip OrderlyMeds' $199–$399/mo Markup: Lock In $49 Semaglutide or $99 Tirzepatide

Both platforms use state-licensed 503A sterile compounding pharmacies and board-certified physicians, yet OrderlyMeds charges 4x more per month. Switch or start at $49/mo (Semaglutide) or $99/mo (Tirzepatide) across all doses with $0 membership fees.

Claim $49 Semaglutide Rate → Claim $99 Tirzepatide Rate →

Unpacking OrderlyMeds' 2026 Pricing vs. Direct 503A Rates

  1. Semaglutide Cost Gap ($199/mo vs. $49/mo): Over a 12-month metabolic protocol, OrderlyMeds patients pay $2,388 out of pocket, whereas Losing Weight RX patients pay $588—a verified net savings of $1,800 per year.
  2. Tirzepatide Cost Gap ($399/mo vs. $99/mo): Dual GIP/GLP-1 therapy on OrderlyMeds costs $4,788 annually versus $1,188 on Losing Weight RX—saving patients $3,600 per year while preserving 100% dose-matching when transferring an existing prescription.

Head-to-Head Comparison: OrderlyMeds vs. Losing Weight RX

Here is how the total annual out-of-pocket costs compare for a patient reaching therapeutic maintenance doses:

Feature / Cost Tier OrderlyMeds Losing Weight RX
Monthly Platform / Membership Fee $0 (Baked into high vial rate) $0 (Free)
Semaglutide Monthly Total (All Doses) $199 / month $49 / month flat rate
Tirzepatide Monthly Total (All Doses) $399 / month $99 / month flat rate
Dose Escalation Price Hikes Flat medication fee, but high base No dose penalties
Pharmacy Quality Standard 503A State-Licensed 503A State-Licensed & Tested
12-Month Out-of-Pocket (Semaglutide) $2,388 – $4,788 total $588 total (Save $1,548/yr)

Why Patients Are Leaving Subscription-Based Telehealth

Direct-to-consumer healthcare is rapidly shifting away from membership-gated models. Chronic weight care requires months of consistent therapy; adding an administrative monthly charge creates unnecessary financial friction.

With Losing Weight RX, there are never any subscription commitments, per-consultation fees, or cancellation penalties. You pay one transparent flat fee for your doctor review, compound formulation, and delivery.

Frequently Asked Questions

Is OrderlyMeds cheaper than Losing Weight RX?

No. OrderlyMeds charges $199/month for Semaglutide and $399/month for Tirzepatide, which is 4x higher than Losing Weight RX's $49/month Semaglutide and $99/month Tirzepatide all-inclusive flat rates.

Can I transfer my OrderlyMeds prescription to Losing Weight RX at my current dose?

Yes. Simply upload a photo of your current OrderlyMeds vial or prescription label during the 2-minute intake so our reviewing physician can match or advance your therapeutic dosage without restarting at a starter dose.

Are shipping and syringes included in the $49 and $99 flat rates?

Yes. Every monthly shipment includes physician consultation, sterile 503A compounded medication, U-100 insulin syringes, alcohol prep pads, and free insulated express cold-chain delivery.

Get Started with $0 Membership Fees →

2026 Verified GLP-1 Cash-Cost & U-100 Syringe Unit Benchmark

Independent pharmacoeconomic comparison of flat-rate Section 503A compounded protocols (pure base API only, $0 monthly membership fee) versus brand-name cash list prices, paired with standard U-100 insulin syringe unit calibration.

Protocol / Active Ingredient 2026 Cash Rate Membership Fee U-100 Syringe Range Clinical Trial Reference
503A Compounded Semaglutide (Base API) $49/mo flat $0 / mo 10–96 units (2.5 mg/mL vial) STEP-1 (NEJM 2021)
503A Compounded Tirzepatide (Base API) $99/mo flat $0 / mo 12.5–75 units (20 mg/mL vial) SURMOUNT-1 (NEJM 2022)
Brand-Name Wegovy® / Zepbound® $1,086–$1,349/mo $0–$145 / mo Pre-filled auto-injector pen SELECT CVOT (NEJM 2023)
52-Week GLP-1 Cost-Per-mg Calculator → Vial mg/mL to U-100 Units Converter → 2026 Open-Data Titration Cost Dataset → View Transparent $49/$99 Flat-Rate Pricing →
Authored by Claire Bennett, M.S. · Medically Reviewed by Dr. Elena Rivera, M.D.
Last Reviewed:
FDA Boxed Warning — Risk of Thyroid C-Cell Tumors: GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) have caused thyroid C-cell tumors in rodent studies; human relevance has not been determined. Absolute Contraindications: Do not use if you have (1) a personal or family history of Medullary Thyroid Carcinoma (MTC), (2) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), (3) a history of acute or chronic pancreatitis, (4) active pregnancy, planned pregnancy within 2 months, or breastfeeding, or (5) a known serious hypersensitivity reaction to semaglutide, tirzepatide, or any excipient.

Section 503A Compounding & Pure Base-API Notice: Compounded medications are prepared by state-licensed U.S. Section 503A pharmacies pursuant to an individualized prescription under 21 U.S.C. § 353a and are not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness, or quality. Losing Weight RX partner pharmacies strictly compound with pure base API only and prohibit FDA-unapproved salt forms (semaglutide sodium or semaglutide acetate). Consult a licensed clinician via clinical eligibility screening before starting therapy.

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in OrderlyMeds Tirzepatide Pricing vs. Losing Weight RX is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J. S., Selzer, F., Paltiel, A. D., & Losina, E. (2025). The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity. Annals of internal medicine, 178(11), 1549-1560. https://doi.org/10.7326/ANNALS-24-03609
  2. Capehorn, M., Johansson, E., Davies, A., Evans, J., Godbeer, F., van Hest, N., Cotterill, G., & Tolley, K. (2025). Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective. Advances in therapy, 42(10), 5055-5071. https://doi.org/10.1007/s12325-025-03288-3
  3. Liu, L., Cui, J., Neidecker, M. V., & Nahata, M. C. (2025). Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States. Journal of managed care & specialty pharmacy, 31(5), 441-450. https://doi.org/10.18553/jmcp.2025.31.5.441
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. U.S. Food and Drug Administration. (2025). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know